Combigan
NDC 54868-6295
Product Information
Combigan is a NDA-approved product labeled by Physicians Total Care, Inc.. This combination medication is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (e. It is supplied as a product. This product entry covers the primary NDC 54868-6295 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 54868-6295?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- BRIMONIDINE TARTRATE (UNII: 4S9CL2DY2H)
- BRIMONIDINE (UNII: E6GNX3HHTE) (Active Moiety)
- TIMOLOL MALEATE (UNII: P8Y54F701R)
- TIMOLOL (UNII: 817W3C6175) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)
- SODIUM PHOSPHATE, MONOBASIC (UNII: 3980JIH2SW)
- SODIUM PHOSPHATE, DIBASIC (UNII: GR686LBA74)
- WATER (UNII: 059QF0KO0R)
- HYDROCHLORIC ACID (UNII: QTT17582CB)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 861635 - brimonidine tartrate 0.2 % / timolol maleate 0.5 % Ophthalmic Solution
- RxCUI: 861635 - brimonidine tartrate 2 MG/ML / timolol 5 MG/ML Ophthalmic Solution
- RxCUI: 861635 - brimonidine tartrate 0.2 % / timolol 0.5 % (as timolol maleate 6.8 MG/ML) Ophthalmic Solution
- RxCUI: 861637 - Combigan 0.2 % / 0.5 % Ophthalmic Solution
- RxCUI: 861637 - brimonidine tartrate 2 MG/ML / timolol 5 MG/ML Ophthalmic Solution [Combigan]
* Please review the full disclaimer at the bottom of this page.